Trial Profile
The Study of Immunotherapy With Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Adult Patients With Persistent and Chronic Immune Thrombocytopenia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Mycophenolate mofetil (Primary) ; Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 10 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Jan 2017 Planned initiation date changed from 1 Jun 2016 to 1 Jun 2019.
- 11 Jan 2016 New trial record